Advocate Aurora Health, Advocate Aurora Research Institute, Milwaukee, WI, USA; Advocate Aurora Health, Aurora Neuroscience Innovation Institute, Milwaukee, WI, USA.
Advocate Aurora Health, Advocate Aurora Research Institute, Milwaukee, WI, USA; School of Dentistry, Marquette University, Milwaukee, WI, USA.
Breast. 2020 Dec;54:8-14. doi: 10.1016/j.breast.2020.08.010. Epub 2020 Aug 22.
Due to its rarity, few studies have characterized the epidemiology of male breast cancer. The purpose of this study was to determine survival and risk factors for male breast cancer in a large U.S.
In this study, 19,795 male patients with breast cancer were identified from the National Cancer Database (2004-2014). Patient demographics, tumor characteristics and treatments were analyzed by using descriptive statistics. We used multivariate Cox regression and Kaplan Meier analysis.
Over 10 years, the incidence of male breast cancer increased from 7.2% to 10.3%, while mortality decreased from 11% to 3.8%. Socioeconomic factors predicting mortality included income medium, and high vs low (HR = 0.78; 0.68), private vs no insurance (HR = 0.73) and the academic research facility vs community cancer center (HR = 0.79). Significant predictors of all-cause mortality included age (HR = 1.04), tumor size (HR = 1.01), hormone receptor expression (HR = 0.8) and cancer stage I vs II, III, and IV at the time of diagnosis (HR = 1.5, 2.7, 4.4, 9.9 respectively). Other predictors of mortality include surgery (HR = 0.4), chemotherapy (HR = 0.8), radiation (HR = 0.8), and hormonal therapy (HR-0.8).
Socioeconomic factors, cancer stage, tumor characteristics (size and grade), and high Charlson-Dayo score contributed to higher mortality among male patients diagnosed with breast cancer. Surgery was most effective, followed by radiation, chemotherapy, and hormonal therapy. Patients with positive ER or PR expression demonstrated better survival. Adjusting for socioeconomic factors, biomarker identification and timely, appropriately chosen treatment are likely to reduce the risk for mortality.
由于其罕见性,很少有研究描述男性乳腺癌的流行病学。本研究旨在确定美国大型数据库中男性乳腺癌的生存情况和危险因素。
本研究从国家癌症数据库(2004-2014 年)中确定了 19795 名男性乳腺癌患者。使用描述性统计方法分析患者的人口统计学特征、肿瘤特征和治疗方法。我们使用多变量 Cox 回归和 Kaplan-Meier 分析。
在过去的 10 年中,男性乳腺癌的发病率从 7.2%增加到 10.3%,而死亡率从 11%下降到 3.8%。预测死亡率的社会经济因素包括收入中等和高与低(HR=0.78;0.68)、私人保险与无保险(HR=0.73)以及学术研究机构与社区癌症中心(HR=0.79)。全因死亡率的显著预测因素包括年龄(HR=1.04)、肿瘤大小(HR=1.01)、激素受体表达(HR=0.8)以及诊断时的癌症分期 I 期与 II、III、IV 期(HR 分别为 1.5、2.7、4.4、9.9)。死亡率的其他预测因素包括手术(HR=0.4)、化疗(HR=0.8)、放疗(HR=0.8)和激素治疗(HR=0.8)。
社会经济因素、癌症分期、肿瘤特征(大小和分级)和高 Charlson-Dayo 评分是男性乳腺癌患者死亡率较高的原因。手术是最有效的治疗方法,其次是放疗、化疗和激素治疗。ER 或 PR 表达阳性的患者生存情况更好。调整社会经济因素、生物标志物鉴定以及及时、适当选择治疗方法可能会降低死亡率。